RBM3 suppresses the CD44v8 to v10 variant and increases the CD44s (standard CD44, lacking variable exons) variant, reducing PCa invasiveness and metastatic ability and offering a new avenue for addressing PCa bone metastases [249]. The gene discussed is RBM3; the disease is posterior cortical atrophy.